ORAMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
ORAMED PHARMACEUTICALS INC. (ORMP) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $2.45 per share as of 2023-05-01, per its 10-K filed 2024-03-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2024-03-06
- 2023-05-01: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.45.
- 2022-09-18: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $3.91.
- 2022-07-28: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $8.47.
- 2022-05-02: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $5.14.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2023-05-01 | $2.45 10-K · filed 2024-03-06 |
| 2022-09-18 | $3.91 10-Q · filed 2022-11-10 |
| 2022-07-28 | $8.47 10-K · filed 2024-03-06 |
| 2022-05-02 | $5.14 10-Q · filed 2022-11-10 |
| 2022-01-03 | $12.03 10-Q · filed 2022-11-10 |
| 2021-08-04 | $15.10 10-K · filed 2023-03-06 |
| 2021-02-17 | $11.33 10-K · filed 2023-03-06 |
| 2021-02-03 | $10.40 10-K · filed 2023-03-06 |
| 2020-01-08 | $4.80 10-K · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |